FARMINGDALE, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal first quarter ended October 31, 2024. First Quarter Highlights Enzo ended the first quarter with aggregate cash and cash equivalents of $47.7 million. The net cash used in operating activities during the first quarter decreased by $4.4 million compared to the prior... Read More

FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock. Full Year Highlights The Company's revenues in the 2024 period of... Read More

FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024. Third Quarter Highlights The Company's Life Science division's third-quarter revenue of $8.0 million improved year-over-year by 7%, marking four consecutive quarters of revenue growth compared to the prior year quarterly periods.... Read More

FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights The Company's Life Science division's second-quarter revenue of $8.5 million improved year-over-year by 14%. During the 2024 period, we experienced a 25% revenue increase in the United States, driven by... Read More

FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fiscal Year 2023 Annual Shareholder Meeting Proposals Proposal One – The shareholders elected Kara Cannon, Steven J. Pully, Bradley L. Radoff, and Mary Tagliaferri,... Read More

FARMINGDALE, NY, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the first quarter ended October 31, 2023. First Quarter Highlights The Company's Life Sciences division's first quarter revenue improved year-over-year by 10% driven by increased demand in multiple product areas, and stability in our multi-pronged channel to market approach. The... Read More

FARMINGDALE, NY, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fourth quarter ended July 31, 2023, and the fiscal year ended July 31, 2023, and also provided a general business update. Fourth Quarter Highlights In July 2023, Enzo Biochem closed on the sale of assets used in the operation of Enzo Clinical Labs for a cash purchase price of... Read More

FARMINGDALE, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading life sciences company, announced today that Steven J. Pully has been appointed to the Company’s Board of Directors effective October 26, 2023. Mr. Pully will assume the role of Chairperson of the Board, and Chair of the Audit Committee as well. “In 2023, Enzo completed the divestiture of Enzo Clinical Labs,... Read More

FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo’s Chief Operating Officer, Kara Cannon, assuming the role of interim CEO. “We thank Hamid for the commitment he has brought to Enzo Biochem, Inc.” Chairperson... Read More

Significant value unlocked for Enzo shareholders with continued focus on life sciences. FARMINGDALE, NY, July 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has closed a transaction to sell certain assets of Enzo’s Clinical laboratory division (Enzo Clinical Labs) to Laboratory Corporation of America Holdings (Labcorp) (NYSE:LH) pursuant to an Asset Purchase Agreement dated March 16, 2023,... Read More

Enzo Life Sciences reports revenue of $7.5 million, with margin improvement in Q3 FY23 FARMINGDALE, NY, June 14, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, today filed its Form 10-Q for the third quarter ended April 30, 2023 of Fiscal Year 2023 (Q3 FY23). Enzo Biochem will not be hosting a financial webcast or call for this most recent quarterly reporting period.... Read More

FARMINGDALE, NY, May 22, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), announced today that the preliminary voting results from the Inspector of Election at today’s Special Meeting of the Shareholders indicate that the Asset Sale Proposal was approved by the affirmative vote of a majority of Enzo’s outstanding common stock. Pending final results of the vote, Enzo will have obtained shareholder approval and met all... Read More

FARMINGDALE, NY, April 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo Biochem” or the “Company”), a leading biosciences and diagnostics company, today announced that its special meeting of shareholders (the “Special Meeting”) to consider and vote on a proposal to approve the sale (the “Asset Sale”) of substantially all the assets and assignment of certain liabilities of its clinical laboratory business to... Read More

Company entered into an Asset Purchase Agreement for substantially all of the operating assets of the Clinical Labs division Enzo Life Sciences reports revenue of $7.5 million, with Jan-23 revenue of $3.6M as the second highest monthly revenue in over 10 years FARMINGDALE, NY, March 21, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, filed its Form 10-Q for the second... Read More

Significant value unlocked for Enzo shareholders with continued focus on remaining businesses. FARMINGDALE, NY, March 16, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) announced today that it has entered into an agreement for Labcorp (NYSE: LH) to acquire the assets of Enzo’s Clinical Laboratory division (Enzo Clinical Labs). The transaction between two leading global life sciences companies follows several steps... Read More

Enzo Life Sciences reports revenue of $7.1 million and 9% growth in Q1 FY 2023, excluding FX Engagement with investment bank to provide advisory services including the evaluation of strategic alternatives for the Company is progressing well. Continuing to make progress in market expansion of the current product portfolio, commercialization of the Company’s offerings, and optimization of the clinical service segment.... Read More